PMID- 26866024
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160211
LR  - 20200930
IS  - 2287-3651 (Print)
IS  - 2287-366X (Electronic)
IS  - 2287-3651 (Linking)
VI  - 5
IP  - 1
DP  - 2016 Jan
TI  - A potent multivalent vaccine for modulation of immune system in atherosclerosis: 
      an in silico approach.
PG  - 50-9
LID - 10.7774/cevr.2016.5.1.50 [doi]
AB  - PURPOSE: Atherosclerosis is classically defined as an immune-mediated disease 
      characterized by accumulation of low-density lipoprotein cholesterol over intima 
      in medium sized and large arteries. Recent studies have demonstrated that both 
      innate and adaptive immune responses are involved in atherosclerosis. In 
      addition, experimental and human models have recognized many autoantigens in 
      pathophysiology of this disease. Oxidized low-density lipoproteins, beta2 
      glycoprotein I (beta-2-GPI), and heat shock protein 60 (HSP60) are the best studied 
      of them which can represent promising approach to design worthwhile vaccines for 
      modulation of atherosclerosis. MATERIALS AND METHODS: In silico approaches are 
      the best tools for design and evaluation of the vaccines before initiating the 
      experimental study. In this study, we identified immunogenic epitopes of HSP60, 
      ApoB-100, and beta-2-GPI as major antigens to construct a chimeric protein through 
      bioinformatics tools. Additionally, we have evaluated physico-chemical 
      properties, structures, stability, MHC binding properties, humoral and cellular 
      immune responses, and allergenicity of this chimeric protein by means of 
      bioinformatics tools and servers. RESULTS: Validation results indicated that 
      89.1% residues locate in favorite or additional allowed region of Ramachandran 
      plot. Also, based on Ramachandran plot analysis this protein could be classified 
      as a stable fusion protein. In addition, the epitopes in the chimeric protein had 
      strong potential to induce both the B-cell and T-cell mediated immune responses. 
      CONCLUSION: Our results supported that this chimeric vaccine could be effectively 
      utilized as a multivalent vaccine for prevention and modulation of 
      atherosclerosis.
FAU - Karkhah, Ahmad
AU  - Karkhah A
AUID- ORCID: 0000-0002-9511-7839
AD  - Cellular and Molecular Biology Research Center, Student Research Committee, 
      School of Medicine, Babol University of Medical Sciences, Babol, Iran.
FAU - Amani, Jafar
AU  - Amani J
AUID- ORCID: 0000-0002-5155-4738
AD  - Applied Microbiology Research Center, Baqiyatallah University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20160127
PL  - Korea (South)
TA  - Clin Exp Vaccine Res
JT  - Clinical and experimental vaccine research
JID - 101592344
PMC - PMC4742599
OTO - NOTNLM
OT  - Apolipoprotein B-100
OT  - Atherosclerosis
OT  - Beta 2-glycoprotein I
OT  - HSP60
OT  - Vaccine
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2016/02/13 06:00
MHDA- 2016/02/13 06:01
PMCR- 2016/01/01
CRDT- 2016/02/12 06:00
PHST- 2015/09/08 00:00 [received]
PHST- 2015/10/22 00:00 [revised]
PHST- 2015/11/05 00:00 [accepted]
PHST- 2016/02/12 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/02/13 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.7774/cevr.2016.5.1.50 [doi]
PST - ppublish
SO  - Clin Exp Vaccine Res. 2016 Jan;5(1):50-9. doi: 10.7774/cevr.2016.5.1.50. Epub 
      2016 Jan 27.